Genocea Biosciences (GNCA) Analyzed By Cantor Fitzgerald with $5.0 Target; Hartline Investment Has Trimmed Its Wisdomtree Investments (WETF) Holding

Among 8 analysts covering Genocea Biosciences (NASDAQ:GNCA), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Genocea Biosciences has $4000 highest and $3 lowest target. $12’s average target is 1065.05% above currents $1.03 stock price. Genocea Biosciences had 17 analyst reports since August 6, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, August 9 by Cowen & Co. The stock of Genocea Biosciences, Inc. (NASDAQ:GNCA) has “Buy” rating given on Monday, September 25 by Cowen & Co. Piper Jaffray maintained Genocea Biosciences, Inc. (NASDAQ:GNCA) on Thursday, August 6 with “Overweight” rating. As per Tuesday, August 11, the company rating was maintained by Needham. FBR Capital maintained Genocea Biosciences, Inc. (NASDAQ:GNCA) on Monday, October 19 with “Outperform” rating. The stock of Genocea Biosciences, Inc. (NASDAQ:GNCA) earned “Hold” rating by Needham on Tuesday, September 26. The rating was downgraded by Stifel Nicolaus to “Hold” on Tuesday, September 26. Needham maintained the shares of GNCA in report on Thursday, September 29 with “Buy” rating. As per Tuesday, October 20, the company rating was maintained by Needham. The firm has “Buy” rating by Cantor Fitzgerald given on Monday, March 5.

Hartline Investment Corp decreased Wisdomtree Investments (WETF) stake by 31.16% reported in 2017Q3 SEC filing. Hartline Investment Corp sold 45,575 shares as Wisdomtree Investments (WETF)’s stock rose 7.07%. The Hartline Investment Corp holds 100,668 shares with $1.03M value, down from 146,243 last quarter. Wisdomtree Investments now has $1.33 billion valuation. The stock increased 1.55% or $0.15 during the last trading session, reaching $9.84. About 1.13M shares traded. WisdomTree Investments, Inc. (NASDAQ:WETF) has declined 9.35% since March 6, 2017 and is downtrending. It has underperformed by 26.05% the S&P500.

Analysts await Genocea Biosciences, Inc. (NASDAQ:GNCA) to report earnings on May, 3. They expect $-0.20 EPS, up 58.33% or $0.28 from last year’s $-0.48 per share. After $-0.37 actual EPS reported by Genocea Biosciences, Inc. for the previous quarter, Wall Street now forecasts -45.95% EPS growth.

Genocea Biosciences, Inc., a biopharmaceutical company, engages in developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. The company has market cap of $84.56 million. The firm uses AnTigen Lead Acquisition System , its proprietary discovery platform to build a pipeline of immunotherapies and its first neoantigen cancer vaccine. It currently has negative earnings. The Company’s lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase 2 trial for the treatment of genital herpes infections.

The stock increased 1.98% or $0.02 during the last trading session, reaching $1.03. About 894,656 shares traded. Genocea Biosciences, Inc. (NASDAQ:GNCA) has risen 67.22% since March 6, 2017 and is uptrending. It has outperformed by 50.52% the S&P500.

Among 13 analysts covering WisdomTree Investments (NASDAQ:WETF), 4 have Buy rating, 3 Sell and 6 Hold. Therefore 31% are positive. WisdomTree Investments has $31 highest and $6.50 lowest target. $15.67’s average target is 59.25% above currents $9.84 stock price. WisdomTree Investments had 49 analyst reports since August 4, 2015 according to SRatingsIntel. The rating was upgraded by Keefe Bruyette & Woods to “Hold” on Tuesday, November 14. On Wednesday, November 2 the stock rating was initiated by UBS with “Sell”. Jefferies maintained it with “Buy” rating and $15.0 target in Wednesday, January 10 report. The rating was upgraded by Citigroup on Monday, May 15 to “Buy”. Wood upgraded WisdomTree Investments, Inc. (NASDAQ:WETF) on Tuesday, November 14 to “Market Perform” rating. Bank of America maintained the shares of WETF in report on Monday, February 5 with “Underperform” rating. The rating was maintained by Northland Capital with “Hold” on Friday, July 28. The firm has “Sell” rating given on Sunday, August 13 by Keefe Bruyette & Woods. Citigroup maintained it with “Sell” rating and $6.50 target in Monday, October 31 report. The stock of WisdomTree Investments, Inc. (NASDAQ:WETF) has “Buy” rating given on Tuesday, February 6 by Citigroup.

Investors sentiment decreased to 1.14 in 2017 Q3. Its down 0.03, from 1.17 in 2017Q2. It turned negative, as 22 investors sold WETF shares while 56 reduced holdings. 24 funds opened positions while 65 raised stakes. 118.39 million shares or 5.96% less from 125.89 million shares in 2017Q2 were reported. Cubist Systematic Strategies Ltd holds 18,053 shares or 0.01% of its portfolio. Shanda Asset Mngmt Ltd accumulated 1.7% or 1.25 million shares. Thrivent For Lutherans stated it has 0% in WisdomTree Investments, Inc. (NASDAQ:WETF). Renaissance Tech Ltd Liability invested in 120,200 shares. Cap Ww Invsts stated it has 6.80M shares or 0.02% of all its holdings. Cibc World Inc holds 0% or 58,740 shares. 12,654 are owned by Jane Street Group Limited. Walleye Trading Lc stated it has 138,321 shares or 0.01% of all its holdings. Proshare Ltd Llc has 10,173 shares for 0% of their portfolio. Hl Financial Ser Limited, a Kentucky-based fund reported 286,933 shares. Us Bancorp De, Minnesota-based fund reported 184 shares. Retail Bank Of America Corporation De stated it has 0% in WisdomTree Investments, Inc. (NASDAQ:WETF). Invesco Limited has 2.88M shares for 0.01% of their portfolio. First Manhattan reported 4,617 shares. Profund Ltd Llc accumulated 17,078 shares or 0.01% of the stock.

Analysts await WisdomTree Investments, Inc. (NASDAQ:WETF) to report earnings on April, 27. They expect $0.08 EPS, up 60.00% or $0.03 from last year’s $0.05 per share. WETF’s profit will be $10.78 million for 30.75 P/E if the $0.08 EPS becomes a reality. After $0.04 actual EPS reported by WisdomTree Investments, Inc. for the previous quarter, Wall Street now forecasts 100.00% EPS growth.